ArticleNoro psikiyatri arsivi2026
The Role of Amphiregulin and Epidermal Growth Factor Receptor in First-Episode Psychosis: Exploring Links to Schizophrenia Pathophysiology.
Article in Noro psikiyatri arsivi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Despite these efforts, the pathogenesis of schizophrenia remains unclear. Recent studies suggest that excessive synaptic pruning during adolescence may contribute to schizophrenia, potentially linking it to uncontrolled apoptosis. Given its role in inflammation and apoptosis, amphiregulin may play a key role in this process. The objective of this study was to investigate the role of the Amphiregulin/Epidermal Growth Factor Receptor (EGFR) complex in the pathogenesis of schizophrenia. Methods: Seventy-three drug-naive patients who were admitted to our outpatient clinic or hospitalized in our clinic and diagnosed for the first time with a psychotic disorder spectrum according to Diagnostic Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), along with 77 healthy controls matched for sociodemographic characteristics and who did not have a history of psychiatric or chronic diseases were recruited for the study. The patients' symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS), administered by a skilled psychiatrist. Blood samples were collected from all participants to measure amphiregulin and EGFR levels. Results: A statistically significant positive correlation was found between amphiregulin and EGFR levels in the patient group. However, there was no significant difference in serum amphiregulin and EGFR levels between the first-episode psychosis group and the healthy control group. Additionally, a positive correlation was observed between both age and age of onset of the disease and serum EGFR levels in the patient group, a correlation that was not present in the healthy control group. Conclusion: The similar correlation between amphiregulin and its receptor in the central nervous system suggests that amphiregulin levels may play a stable role in the disease process rather than being a primary driver of disease development. It remains unclear whether plasma neurotrophins accurately reflect central neurotrophic activity. The presence of amphiregulin in serum, which is thought to be secreted by regulatory T cells (Tregs) in the central nervous system, may be low. Further studies using cerebrospinal fluid and brain tissue samples are particularly needed in schizophrenia research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.